Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619951 | 1.00 | NLRP3 (0.38) | NLRP3TLR7TLR8PROKR1BTK | |
| SCHEMBL26713574 | 0.94 | NLRP3 (0.38) | NLRP3TLR7TLR8PROKR1BTK | |
| SCHEMBL26619807 | 0.93 | NLRP3 (0.41) | NLRP3TLR7TLR8PROKR1BTK | |
| SCHEMBL26619812 | 0.93 | NLRP3 (0.41) | NLRP3TLR7TLR8PROKR1BTK | |
| SCHEMBL26713577 | 0.92 | NLRP3 (0.39) | NLRP3TLR7TLR8PROKR1BTK | |
| SCHEMBL26713582 | 0.92 | MAP3K12 (0.41) | NLRP3PROKR1KDM4EGAAMAPK1 | |
| SCHEMBL26713580 | 0.92 | NLRP3 (0.37) | NLRP3TLR7TLR8PROKR1BTK | |
| SCHEMBL26713579 | 0.91 | NLRP3 (0.38) | NLRP3TLR7TLR8PROKR1GAA | |
| SCHEMBL26713586 | 0.91 | ALDH1A1 (0.39) | NLRP3TLR7TLR8BTKMAPK1 | |
| SCHEMBL30074831 | 0.90 | JAK2 (0.40) | NLRP3TLR7TLR8BTKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348458-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115244052-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348458-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885TLR7 238/4885TLR8 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.